| Name |
|---|
SMAR GeneSpinal muscular atrophy, chronic distal, autosomal recessive |
SMAL Genespinal muscular atrophy, congenital nonprogressive, of lower limbs |
SMAJ GeneSpinal muscular atrophy, Jokela type |
SPPM Genescapuloperoneal syndrome, myopathic type |
LOC101060022 Genenascent polypeptide-associated complex subunit alpha, muscle-specific form-like |
LOC101928892 Genenascent polypeptide-associated complex subunit alpha, muscle-specific form-like |
LOC100422315 Genepoly(A) binding protein, cytoplasmic 4 (inducible form) pseudogene |
LOC105379556 Genenascent polypeptide-associated complex subunit alpha, muscle-specific form-like |
PABPC4 Genepoly(A) binding protein, cytoplasmic 4 (inducible form) Poly(A)-binding proteins (PABPs) bind to the poly(A) tail present at the 3-prime ends of most eukaryotic mRNAs. PABPC4 or IPABP (inducible PABP) was isolated as an activation-induced T-cell mRNA encoding a protein. Activation of T cells increased PABPC4 mRNA levels in T cells approximately 5-fold. PABPC4 contains 4 RNA-binding domains and proline-rich C terminus. PABPC4 is localized primarily to the cytoplasm. It is suggested that PABPC4 might be necessary for regulation of stability of labile mRNA species in activated T cells. PABPC4 was also identified as an antigen, APP1 (activated-platelet protein-1), expressed on thrombin-activated rabbit platelets. PABPC4 may also be involved in the regulation of protein translation in platelets and megakaryocytes or may participate in the binding or stabilization of polyadenylates in platelet dense granules. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. This protein has also been found to interact with coronavirus nucleocapsid proteins and is thought to inhibit coronavirus replication. [provided by RefSeq, Nov 2021] |
LOC100422325 Genepoly(A) binding protein, cytoplasmic 4 (inducible form) pseudogene |
LOC101928722 Genenascent polypeptide-associated complex subunit alpha, muscle-specific form-like |
MDRV Genemuscular dystrophy, with rimmed vacuoles |
MLIP Genemuscular LMNA-interacting protein Predicted to enable lamin binding activity and transcription corepressor activity. Predicted to be involved in negative regulation of cardiac muscle hypertrophy in response to stress; negative regulation of transcription by RNA polymerase II; and positive regulation of transcription by RNA polymerase II. Predicted to be located in PML body; nuclear envelope; and sarcolemma. [provided by Alliance of Genome Resources, Mar 2025] |
LGMD1H Genelimb girdle muscular dystrophy 1H (autosomal dominant) |
LGMD1G Genelimb girdle muscular dystrophy 1G (autosomal dominant) |
MDC1B GeneMuscular dystrophy, congenital, 1B |
FSHMD1A Genefacioscapulohumeral muscular dystrophy 1A Facioscapulohumeral muscular dystrophy (FSHD) is a common hereditary disease of muscle. Patients with FSHD have a chromosomal rearrangement within the subtelomeric region of chromosome 4 (4q35). This region is composed mainly of a polymorphic repeat structure consisting of 3.3 kb repeat units, designated D4Z4. The number of repeat units varies from 10 to more than 100 in the population, however, in FSHD patients only 1-10 repeat units is observed because of a deletion of an integral number of these units. FSHD is caused by an epigenetic mechanism involving the contraction of a subtelomeric macrosatellite repeat, which results in marked hypomethylation of the contracted D4Z4 allele. It is likely not the structure, but the deregulation of transcription of one or more genes as a result of repeat-contraction-mediated chromatin alterations, that causes FSHD. [provided by RefSeq, Sep 2011] |
FSHMD1B Genefacioscapulohumeral muscular dystrophy 1B |
SCA18 Genespinocerebellar ataxia 18 (sensory with neurogenic muscular atrophy) |
MDCMP Genemuscular dystrophy, congenital, merosin-positive |